Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma

Development of drug resistance limits the efficacy of targeted therapies. Alternative approaches using different combinations of therapeutic agents to inhibit several pathways could be a more effective strategy for treating cancer. The effects of the approved epidermal growth factor receptor (EGFR)-...

Descripción completa

Detalles Bibliográficos
Autores principales: Jeannot, Victor, Busser, Benoit, Vanwonterghem, Laetitia, Michallet, Sophie, Ferroudj, Sana, Cokol, Murat, Coll, Jean-Luc, Ozturk, Mehmet, Hurbin, Amandine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108607/
https://www.ncbi.nlm.nih.gov/pubmed/27877053
http://dx.doi.org/10.2147/OTT.S117743

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5108607/
https://www.ncbi.nlm.nih.gov/pubmed/27877053
http://dx.doi.org/10.2147/OTT.S117743

Ejemplares similares